Physician profile
Min Chi
NPI 1922434521
$6,864.31
in general payments reported to CMS, 2019-2025
33 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $1,154 · 2023: $1,243 · 2024: $1,906 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,489.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,363.41 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $641.33 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $581.07 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $452.77 | 2024-2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $371.42 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $342.18 | 2022-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $316.21 | 2023-2025 | Onpattro, Amvuttra |
| Cvrx, INC. | $309.89 | 2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $260.86 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $253.69 | 2023-2025 | |
| Abiomed | $248.38 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.42 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $180.00 | 2022-2025 | Camzyos |
| Pfizer INC. | $143.80 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $142.13 | 2023-2025 | Assure Wcd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $132.29 | 2023-2024 | Repatha |
| Scpharmaceuticals INC. | $101.20 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $98.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $90.20 | 2021 | |
| Bridgebio Pharma, INC. | $80.23 | 2025 | Attruby |
| Atricure, INC. | $77.94 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| United Therapeutics Corporation | $73.52 | 2024-2025 | Tyvaso, Tyvaso, Orenitram |
| Kiniksa Pharmaceuticals, LTD. | $71.63 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.24 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $67.83 | 2024-2025 | |
| Bard Access Systems, INC. | $58.33 | 2021-2022 | |
| Boston Scientific Corporation | $30.35 | 2024 | Watchman Flx |
| Lilly USA, LLC | $24.45 | 2025 | Zepbound |
| Daiichi Sankyo INC. | $24.05 | 2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $22.81 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $21.59 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $18.39 | 2022 | |
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.